A randomized controlled trial of intranasal ketamine in major depressive disorder

KAB Lapidus, CF Levitch, AM Perez, JW Brallier… - Biological …, 2014 - Elsevier

Abstract

Background The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered via an intravenous route, has shown rapid antidepressant effects in patients with treatment-resistant depression. The current study was designed to test the safety, tolerability, and …

Last updated: Jul 27, 2020